Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure

The FDA‐approved immune checkpoint inhibitors, nivolumab and pembrolizumab, are the most recent biological therapies in the therapeutic armamentarium for recurrent metastatic head and neck squamous cell carcinomas. This article highlights the tools for analyzing the costeffectiveness of such therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Santana‐Davila, Rafael, Rodriguez, Cristina P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813756/
https://www.ncbi.nlm.nih.gov/pubmed/29192017
http://dx.doi.org/10.1634/theoncologist.2017-0527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813756/
https://www.ncbi.nlm.nih.gov/pubmed/29192017
http://dx.doi.org/10.1634/theoncologist.2017-0527

Ejemplares similares